Marker Therapeutics Inc. has released a corporate presentation detailing the advancements and strategic positioning of its MAR-T Cell Platform, a non-genetically engineered technology developed at Baylor College of Medicine. The presentation highlights the lead clinical product, MT-601, which targets six tumor-specific antigens and has shown promising results in a Phase 1 clinical trial with a 78% response rate in lymphoma patients. The MAR-T technology is designed for both blood and solid tumors, offering a favorable safety profile without the risk of immune-effector cell associated neurotoxicity syndrome (ICANS). Marker Therapeutics has multiple FDA-cleared INDs for MAR-T based clinical programs and has secured over $30 million in non-dilutive funding. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.